Nurse Practitioner, Primary Care · Paterson, NJ
NPI
1669836334
Since 2016
Specialty
Nurse Practitioner, Primary Care
Code 363LP2300X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
11 Getty Avenue
Paterson, NJ, 07503
Phone (973) 754-4701
Groups this clinician bills Medicare through
Medicare paid, 2024
$3,015
49 services
Medicare patients, 2024
18
Average age 65
Drug cost, 2024
$4.4M
2,969 prescriptions
Company payments, 2025
$1,423
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Desiree Ferrandiz was code 99214 (office e&m - established), 41 times for 17 patients. In total Desiree Ferrandiz billed 49 services in 7 codes, and Medicare paid $3,015.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-09-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 41 | 17 | $61.33 | $2,514 |
By year: 2022 $3,255 for 65 services; 2023 $2,538 for 43 services; 2024 $3,015 for 49 services.
Medicare prescription drug claims, 2024
In 2024, the drug Desiree Ferrandiz prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 310 prescriptions and refills. In total Desiree Ferrandiz wrote 2,969 Medicare prescriptions that cost $4.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 310 | 328 | 35 | $1.3M |
| Tivicay Dolutegravir Sodium | 216 | 224 | 22 | $498K |
| Atorvastatin Calcium Generic | 148 | 330 | 35 | $1,671 |
| Rosuvastatin Calcium Generic | 144 | 232 | 23 | $1,710 |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 128 | 141 | 14 | $553K |
| Descovy Emtricitabine/Tenofov Alafenam | 112 | 116 | 11 | $250K |
| Dovato Dolutegravir Sodium/Lamivudine | 96 | 108 | Under 11 | $307K |
| Amlodipine Besylate Generic | 93 | 177 | 18 | $289 |
| Juluca Dolutegravir/Rilpivirine | 92 | 110 | 12 | $380K |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 88 | 104 | Under 11 | $372K |
| Losartan Potassium Generic | 61 | 119 | 11 | $268 |
| Metoprolol Succinate Generic | 55 | 80 | Under 11 | $515 |
| Enalapril Maleate Generic | 55 | 89 | Under 11 | $371 |
| Hydrochlorothiazide Generic | 50 | 99 | 11 | $70.47 |
| Lisinopril Generic | 49 | 85 | Under 11 | $194 |
Brand drugs: 1,441 claims; generic drugs: 1,514 claims; opioid claims: 25.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Desiree Ferrandiz $1,423 ($1,423 in general payments such as food, travel and fees) from 3 companies. The largest payer was Gilead Sciences, Inc. with $875.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.